ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Direct Indexing
    • Disruptive Technology
    • Energy Infrastructure
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Financial Literacy
    • Fixed Income
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Modern Alpha
    • Multifactor
    • Night Effect
    • Portfolio Strategies
    • Responsible Investing
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Dual Impact Channel
  2. FDA Rebound Might Help HART Beat Higher
Dual Impact Channel
Share

FDA Rebound Might Help HART Beat Higher

Tom LydonOct 13, 2022
2022-10-13

Experienced healthcare investors know that the Food & Drug Administration (FDA) often looms large. After all, that is the regulatory body that has the final say in whether or not biotechnology and pharmaceutical companies can bring drugs to market.

Not surprisingly, the FDA’s approval process was set back by the coronavirus pandemic when, in 2020, the priority became evaluating various COVID-19 vaccines. While that effort paid off in terms of several vaccines coming to market, the administration isn’t back to pre-pandemic levels regarding approvals.

Should clinical holds, delays, and other regulatory snafus improve, exchange traded funds, including the IQ Healthy Hearts ETF (HART ), stand to benefit?

“The efficient functioning of the FDA is paramount for the timely advancement of important medicines through the clinic and onto the market,” according to Cowen research. “We believe that understanding the FDA regulatory framework from IND to approval is important for both generalist investors with healthcare exposure and biopharma sector specialists. In this report, we hope to provide not only a resource for the cadence of regulatory interactions that occur throughout the drug development process but also tackle key activities that can have important implications for approval success and stock movement.”

HART, which tracks the IQ Candriam Healthy Hearts Index, is pertinent to the FDA improving evaluation and approval efficiency because the ETF focuses on healthcare companies, among others, working on therapies and treatments for cardiovascular disease. Acknowledging that heart disease is one the biggest health issues in the world. Translation: If the FDA speeds up the approval process for related pharmaceuticals and treatments, HART stands to benefit.

Predictably, there are moving parts here. That’s often the case with any government agency, but HART member firms seeking approvals from the FDA have ways of navigating the often burdensome regulatory landscape. HART holdings have an advantage in that they’re seeking approvals for treatments of a major healthcare problem, and the more compelling their efforts are, the odds shorten of catching regulators’ attention.

“Thus, while FDA reviews are never without risk and the Agency can at times be unpredictable, we believe that products with compelling efficacy and safety data packages will continue to see approvals and that any perceived overly negative sentiment into a regulatory process could be capitalized on,” concludes Cowen.

For more news, information, and strategy, visit the Dual Impact Channel.

Loading Articles...
Our Sites
  • VettaFi
  • Advisor Perspectives
  • ETF Trends
Tools
  • ETF Screener
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Database Pro
More Tools
  • Financial Advisor & RIA Center
Explore ETFs
  • ETF News
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Information
  • Contact Us
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X